-+ 0.00%
-+ 0.00%
-+ 0.00%

Shiseido Company (TSE:4911) Could Be 22% Undervalued Following New Serum Launch

Simply Wall St·09/05/2026 11:23:18
Listen to the news

Why Shiseido’s new serum launch matters for the stock

Shiseido Company (TSE:4911) has introduced the Vital Perfection Intensive SculptDefine Serum, a new lifting skincare product that targets facial sagging using its proprietary D-AminoLift Complex.

The launch leans on clinical data, with all study participants reportedly seeing visible improvements in sagging and radiance. For investors, this raises questions about how new hero products might influence Shiseido’s long term brand strength and revenue mix.

Shiseido Company’s share price has climbed 33.55% over the past 90 days and 49.17% year to date, while the 1-year total shareholder return of 46.33% sits against a weaker 3-year and 5-year total shareholder return. This suggests momentum has improved recently, even as longer term holders still carry meaningful drawdowns.

Spot fresh momentum stories alongside Shiseido Company by scanning our hand picked 71 high quality undiscovered gems that are quietly building brands and products with room to grow.

For Shiseido Company, the recent share price surge and the launch of a clinically backed serum can point to a stronger business story or to a sharp swing in sentiment. How does the current valuation reflect that balance?

Most Popular Narrative: 21.7% Undervalued

On the most followed narrative, Shiseido Company’s fair value of ¥4,400 sits above the last close at ¥3,445, which frames the current share price as a discount to those expectations.

Analysts broadly agree that structural reforms and cost reduction efforts are driving margin expansion, but the accelerated and deeper-than-expected restructuring, especially in the Americas and headquarter operations, puts Shiseido on a path to possibly surpass consensus margin targets and achieve double-digit operating margins ahead of schedule, greatly lifting net margins and earnings.

Read the complete narrative.

Want to see what earnings profile has to line up for that valuation to work? The narrative leans on sharper margins, steadier revenue growth and a richer future earnings multiple. The exact mix of those moving parts might surprise you.

Result: Fair Value of ¥4,400 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Shiseido Company still faces pressure from aging core markets and intense competition from digital native and clean beauty brands, which could limit pricing power and revenue progress.

Find out about the key risks to this Shiseido Company narrative.

Another view on Shiseido Company’s valuation

The SWS DCF model points in a different direction for Shiseido Company. At a share price of ¥3,445, the stock is trading above an estimated future cash flow value of ¥3,226.47. That implies the shares screen as overvalued on this measure. Which set of assumptions do you trust more?

Look into how the SWS DCF model arrives at its fair value.

4911 Discounted Cash Flow as at Sep 2026
4911 Discounted Cash Flow as at Sep 2026

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Shiseido Company for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 25 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Curious whether the current optimism around Shiseido Company matches the underlying risk reward trade off? Act soon and form your own view by weighing its 1 key reward and 1 important warning sign

Looking for more ideas beyond Shiseido Company?

Do not stop your research with Shiseido Company. Cast the net wider now so you are not looking back wishing you had spotted the next opportunity earlier.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.